A Call to ActionMonoclonal Antibodies for the Prevention and Treatment of COVID-19
This program is intended to educate infectious disease, internal medicine, and other clinicians involved in the management of patients who are at heightened risk for poor outcomes for coronavirus disease 2019 (COVID-19).
Multiple anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) have gained Emergency Use Authorization (EUA) from the US Food and Drug Administration for both treatment and prevention of COVID-19, though the presence of multiple new variants and subvariants has rapidly shifted mAb efficacy and EUA status. Clinicians struggle to remain up to date with a rapidly changing field that has remained a public health concern. A panel of experts will present data on and discuss current evidence and regulatory status for these anti-SARS-CoV-2 mAbs and available antivirals, updates to National Institutes of Health guidelines on patient identification and stratification for both treatment and prevention, implementation through COVID-19 clinic models, and strategies to reduce health care disparities. The panel will utilize additional experts to augment discussion and provide expertise on multiple topics.
Upon completion of this activity, the participant should be better able to:
- Describe the clinical profiles, trial data, and regulatory status for anti-SARS-CoV-2 mAbs for preexposure prophylaxis and treatment
- Identify candidates for preexposure prophylaxis or treatment with anti-SARS-CoV-2 mAbs, including immunocompromised patients
- Collaborate with patients and other clinicians to overcome barriers to the use of anti-SARS-CoV-2 mAbs for preexposure prophylaxis or treatment
6:00–6:10 PM Preactivity Questionnaire and Faculty Introductions
6:10–6:30 PM An Overview of COVID-19 and Anti-SARS-CoV-2 Monoclonal Antibodies
6:30–6:55 PM Best Practices for Preexposure Prophylaxis
6:55–7:25 PM Considerations for COVID-19 Treatment
7:25–7:45 PM Disparities in the Use of Anti-SARS-CoV-2 Monoclonal Antibodies
7:45–8:00 PM Postactivity Questionnaire and Q&A Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Global Education Group designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-108-L01-P)
This is a knowledge-based activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 2.0 contact hours (which includes * hour(s) of pharmacology).
*Pharmacology hour(s) to be determined after clinical content review.
Instructions to Receive Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest with a 70% or better and evaluation form directly after the activity. Pharmacist learners must check the CPE monitor within 30 days of the activity for their credit.
Disclosure of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or email@example.com.
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca.
This is an affiliated event (not official IDWeek programming).